Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1) is a member of the E2 ubiquitin-conjugating enzyme family, catalyzing the covalent attachment of ubiquitin to substrate proteins[5][6]. It is involved in both canonical and noncanonical ubiquitylation, uniquely capable of attaching ubiquitin to not only lysine but also serine, threonine, cysteine, and even complex sugars or glucose residues[1]. UBE2Q1 contains an extended N-terminal domain and an RWD domain, and can function independently of E3 ligases for certain noncanonical substrates. It shows substrate specificity and is implicated in hormonal regulation and potentially tumor biology, although detailed clinical targeting information and drugs are currently lacking[6][1].
Drugs (if developed) would likely act as inhibitors or modulators of protein ubiquitin-conjugation activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1).